 Home > Active Ingredient News > Antitumor Therapy > During ASCO 2021, Ma Jun's team has another major research on nasopharyngeal cancer

During ASCO 2021, Ma Jun's team has another major research on nasopharyngeal cancer

 Last Update: 2021-06-16
 Source: Internet
 Author: User

Tags

sglt2 inhibitors drugs

type 2 inflammation

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 8, during the 2021 American Society of Clinical Oncology (ASCO) annual meeting, "The Lancet" published online a phase 3 randomized controlled clinical trial led by the team of Professor Ma Jun from the Cancer Center Affiliated to Sun Yat-sen University and participating in 14 hospitals in China Result

This trial studied the efficacy and safety of capecitabine rhythm adjuvant chemotherapy for patients with locally advanced nasopharyngeal carcinoma who received radical concurrent radiotherapy and chemotherapy

Thirty-five (17%) of 201 patients in the capecitabine group and 11 (6%) of 200 patients in the standard treatment group reported grade 3 adverse events; hand-foot syndrome was the most related to capecitabine.

The significance of this study is that it is the first phase 3 randomized controlled trial to confirm that capecitabine rhythm chemotherapy adjuvant treatment of high-risk locally advanced nasopharyngeal carcinoma can improve the survival rate of patients

The comment of Professor Robert Kerbel from the University of Toronto in Canada pointed out that the approval of immune checkpoint inhibitors and antibody drug conjugates has increased in recent years, but the huge cost of such drugs has brought more and more to the healthcare system.

During the 2019 ASCO annual meeting, Ma Jun’s team published another nasopharyngeal cancer clinical trial at NEJM, that is, gemcitabine combined with cisplatin (GP) induction chemotherapy before concurrent radiotherapy and chemotherapy

He has been engaged in the treatment of nasopharyngeal carcinoma for 30 years, and his main research direction is radiotherapy and comprehensive treatment of nasopharyngeal carcinoma.

References: Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial, Published: June 07, 2021DOI: https://doi.

This kind of nasopharyngeal cancer patients receiving capecitabine rhythm chemotherapy can significantly improve the 3-year tumor-free survival rate and overall survival rate, and the safety is better.

The publication of the results of this trial is expected to rewrite the NCCN guidelines on adjuvant treatment of high-risk nasopharyngeal carcinoma

The addition of GP induction chemotherapy can increase the 3-year tumor-free survival rate of patients from 76.
5% to 85.
3%, and reduce the risk of recurrence or death by 49%; the 3-year overall survival rate will increase from 90.
3% to 94.
6%, and the risk of death will be reduced by 57%
.
This is the first large-scale prospective phase III clinical trial to confirm that the gemcitabine + cisplatin (GP) regimen induction chemotherapy is effective in the treatment of locally advanced nasopharyngeal carcinoma
.
The addition of GP induction chemotherapy can increase the 3-year tumor-free survival rate of patients from 76.
5% to 85.
3%, and reduce the risk of recurrence or death by 49%; the 3-year overall survival rate will increase from 90.
3% to 94.
6%, and the risk of death will be reduced by 57%
.
This is the first large-scale prospective phase III clinical trial to confirm that the gemcitabine + cisplatin (GP) regimen induction chemotherapy is effective in the treatment of locally advanced nasopharyngeal carcinoma
.
Ma Jun, Chief Physician, Chief Physician , Executive Deputy Director, Sun Yat-sen University Cancer Center, Executive Deputy Dean , Sun Yat-sen University Cancer Hospital, Chairman, CSCO Nasopharyngeal Cancer Expert Committee, Chinese Anti-Cancer Association Nasopharyngeal Cancer Professional Committee, and Designated Chairman, State Council Degree Committee Deputy Convenor of the Medical Discipline Review Group , Member of the Standing Committee of the Chinese Medical Association Radiation Oncology Therapeutics Branch, Chairman of the Guangdong Branch of the Chinese Society of Radiation Oncology

Professor Ma Jun graduated from Sun Yat-Sen Medical University (now Sun Yat-Sen University) in 1990 with a master's degree in oncology.
From May 2000 to May 2002, he went to the MD Anderson Cancer Center of the University of Texas for postdoctoral training
.
Now he is the executive deputy director and executive deputy dean of Sun Yat-sen University Cancer Center
.

He has been engaged in the treatment of nasopharyngeal carcinoma for 30 years, and his main research direction is radiotherapy and comprehensive treatment of nasopharyngeal carcinoma.
He has made outstanding achievements in the clinical and translational research of nasopharyngeal carcinoma, a high incidence of nasopharyngeal carcinoma in southern China
.
Increase the 5-year survival rate of nasopharyngeal carcinoma from 60% in the 1990s to 80%, reaching the world's leading level
.
Among them, 4 studies on the clinical staging of nasopharyngeal cancer were directly adopted by the American Cancer Federation/International Union Against Cancer (AJCC/UICC) clinical staging standards and promoted and applied worldwide
.
He is currently a member of the Standing Committee of the Chinese Society of Radiation Oncology, the vice chairman of the Nasopharyngeal Carcinoma Professional Committee of the Chinese Anti-Cancer Association, the deputy chairman of the Tumor Staging Professional Committee of the Chinese Anti-Cancer Association, and the director of the Guangzhou Key Laboratory of Nasopharyngeal Cancer
.
The leader of the innovation team of the Ministry of Education and the Ministry of Science and Technology, a national-level candidate of tens of millions of talents of the Ministry of Human Resources and Social Security, national outstanding scientific and technological workers, young and middle-aged experts with outstanding contributions from the Ministry of Health, experts with special government allowances from the State Council, outstanding professors of the Chinese Medical Foundation of the United States, Winners of Nanyue Baijie, Pearl River Scholars, Ding Ying Science and Technology Award and Wu Jieping-Paul Janssen Medical Pharmacy Award
.
Representative research results were published in the Lancet Oncol, a professional oncology journal under the Lancet (2 articles) and the world’s number one journal in clinical oncology therapeutics, “J Clin Oncol” (2 articles).
"Big News" and "Top Ten Scientific and Technological Advances in Chinese Colleges and Universities"
.
As the first person to complete, he won 5 provincial and ministerial first prizes and 2 national scientific and technological progress second prizes (2009 and 2015)
.
As a senior expert dedicated to the treatment of nasopharyngeal cancer for 30 years, Professor Ma Jun devoted almost all his efforts to the research on this high-incidence tumor in China, which is known as the "Cantonese tumor", especially in the radiotherapy of nasopharyngeal cancer.
With outstanding achievements, he has become a trustworthy tumor fighter in the hearts of the people in South China
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.